書籍詳細

1 リンパ腫の分類と疫学

P.7 掲載の参考文献

• 1) 向井 清:悪性リンパ腫の組織分類. 癌の臨床 34:529-539, 1988.

• 2) Warnke RA, Weiss LM, Chan JKC et al.:Tumors of the lymph nodes and spleen. Atlas of Tumor Pathology. Third series, fascicle 14. Armed Forces Institute of Pathology, Washington, DC, 1995, p53-62.

• 3) 菊池昌弘:日本人の悪性リンパ腫. 病理と臨床 17 (臨増):197-200, 1999.

• 4) Harris NL, Jaffe ES, Stein H et al.:A revised European-American classification of lymphoid neoplasms:A pro-posal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.

• 5) Lymphoma Study Group of Japanese Pathologists:The World Health Organization classification of malignant lymphomas in Japan:Incidence of recently recognized entities. Pathol Int 50:696-702, 2000.

• 6) 須知泰山:悪性リンパ腫の分類:諸分類の解説と相互の関係. 新・悪性リンパ腫アトラス. (須知泰山, 菊池昌弘・編) . 文光堂, 2000, p13-23.

• 7) Jaffe ES, Harris NL, Stein H et al. (eds) :Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. IARC Press, Lyon, 2001.

2 リンパ腫の病態と症候学

P.17 掲載の参考文献

• 1) 松田幹夫, 今井 大:リンパ組織の形態と機能. 病理と臨床 12(臨増) :9-14, 1994.

• 2) 毛利 昇, 斎藤生朗:消化管のリンパ腫. 病理と臨床 12(臨増):209-213, 1994.

• 3) 平沢 興, 岡本道雄:分担解剖学. 第11版. 第2巻. 金原出版, 東京, 1986, p149-158, 377-379.

• 4) Warnke RA, Weiss LM, Chan JKC et al.:Tumors of the Lymph Nodes and Spleen. Atlas of Tumor Pathology, 3rd Series, Fascicle 14. Armed Forces Institute of Pathology, Washington DC, 1995, p10-14.

• 5) Sternberg SS, ed:Histology for Pathologist, 2nd ed. Lippincott-Raven, Philadelphia, 1997, p651-673, 675-684, 687-706.

• 6) Ioachim HL:Lymph Node Pathology, 2nd ed. Lippincott-Raven, Philadelphia, 1994, p3-12.

• 7) Janeway CA Jr, Travers P:Immunobiology. Current Biology Ltd, London,1994, p1-43.

• 8) Inghirami GM, Knowles DM:The Immune System:Structure and Function. Neoplastic Hematopathology Knowles DM, Wiliams and Wilkins, Baltimore, 1992, p27-72.

• 9) 渡辺 昌:悪性リンパ腫病理診断のかなめ. リンパ節生検. 文光堂, 東京, 1985, p27-41.

• 10) Williams PL, Warwick R, Dyson M:The Spleen. Gray's Anatomy, 37th ed. Churchill Livingstone, New York, 1989, p827-832.

• 11) Ritter MA, Crisspe IN:胸腺の構造とその発達. 胸腺. 南江堂, 東京, 1993, p11-29.

• 12) 松谷章司:リンパ球, 形質細胞の増生. 病理と臨床 13:1277-1283, 1995.

• 13) 島峰哲郎:骨髄リンパ球・形質細胞・肥満細胞. 骨髄組織病理アトラス. 文光堂, 東京, 1984, p79-83.

• 14) Bain BJ, Clark DM, Lampert IA:Bone Marrow Pathology. Blackwell Scientific Publications, London, 1992, p52-53.

P.22 掲載の参考文献

• 1) Mosmann TR, Coffman RL:TH1 and TH2 cells:different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145-173, 1989.
  pubmed

• 2) Hsu S-M, Wldron JW, Hsu P-L et al.:Cytokines in malignant lymphomas:Review and prospective evaluation. Hum Pathol 24:1040-1057, 1994.

• 3) Poppema S, Van den Berg A:Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol 10:345-350, 2000.

• 4) Fayad L, Cabanillas F, Talpaz M et al.:High serum interleukin-61evels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma 30:563-571, 1998.
  pubmed

P.26 掲載の参考文献

• 1) Nemazee D:Receptor selection in B and T lymphocytes. Annu Rev Immunol 18:19-51, 2000.

• 2) Hollowood K, Goodlad JR:Germinal centre cell kinetics. J Pathol 185:229-233, 1998.
  pubmed

• 3) Arpin C, Dechanet J, Liu YJ et al.:Generation of memory B cells and plasma cells in vitro. Science 268:720-722, 1995.
  pubmed

• 4) Tangye SG, Liu YJ, de Vries JE et al.:Identification of functional human splenic memory B cells by expression of CD148 and CD27. J Exp Med 188:1691-1703, 1998.
  pubmed

• 5) Willis TG, Dyer MJ:The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 96:808-822, 2000.
  pubmed

• 6) Tamura A, Miura I, Taniwaki M et al.:Interphase detection of immunoglobulin heavy chain gene translocations with specific oncogene loci in 173 patients with B-cell lymphoma. Cancer Genet Cytogenet 129:1-9, 2001.
  pubmed

• 7) Akasaka T, Ueda C, Ohno H et al.:Nonimmunoglobulin (non-Ig) /BCL6 gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig/BCL6. Blood 96:2907-2909, 2000.
  pubmed

• 8) Akagi T, Motegi M, Seto M et al.:A novel gene, MALTl at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 18:5785-5794, 1999.

• 9) Sanchez-Beato M, Saez AI, Piris MA et al.:Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol 159:205-213, 2001.
  pubmed

• 10) Kulwichit W, Edwards RH, Raab-Traub N et al.:Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci 95:11963-11968, 1998.
  pubmed

• 11) Braun DK, Dominguez G, Pellett PE:Human herpesvirus 6. Clin Microbiol Rev 10:521-567, 1997.
  pubmed

• 12) Cesarman E, Chang Y, Knowles DM et al.:Kaposi's sar-coma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas, N Engl J Med 332:1186-1191, 1995.

• 13) Ray RB, Meyer K, Ray R:Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 226:176-182, 1996.
  pubmed

• 14) Ghia P, Boussiotis VA, Nadler LM et al.:Unbalanced expression of bcl-2 family proteins in follicular lymphoma:Contribution of CD40 signaling in promoting survival. Blood 91:244-251, 1998.
  pubmed

P.29 掲載の参考文献

• 1) 高浜洋介:胸腺内でのT細胞の分化とレパートリー形成. T細胞系の免疫学 第3版. (藤原大美), 中外医学社, 東京, 1997, p32-63.

• 2) 河本 宏, 桂 義元:T細胞分化と関連分子. Bio Science新用語ライブラリー 免疫 第2版. (斉藤 隆, 竹森利忠), 羊土社, 東京, 2000, p48-49.

• 3) 吉開泰信:αβT細胞とγδT細胞. Bio Science新用語ライブラリー 免疫 第2版. (斉藤 隆, 竹森利忠) , 羊土社, 東京, 2000, p50-51.

• 4) 矢田純一:リンパ球の発生と分化. 病理と臨床 12 (臨時増刊号 リンパ節病変):2-8, 1994.

• 5) Mackay CR:The concept of memory T cells. Handbook of B and T lymphocytes. (Snow EC) , Academic press, San Diego, 1994, p160-178.

• 6) 西村孝司:Th1/Th2. Bio Science新用語ライブラリー. 免疫 第2版. (斉藤 隆, 竹森利忠), 羊土社, 東京, 2000, p58-59.

• 7) Born W, Kelly KA, O'Brien RL:γδ T cells. Handbook of B and T lymphocytes, (Snow EC) , Academic press, San Diego, 1994, p179-214.

• 8) 清野 宏:IEL/EC/DC/粘膜系. Bio Science新用語ライブラリー 免疫 第2版. (斉藤 隆, 竹森利忠) , 羊土社, 東京, 2000, p36-37.

• 9) 贄田美江, 十字猛夫:ヒトVα24NKT細胞. 最新医学 55:811-817, 2000.
  Medical*Online

• 10) Harris NL, Jaffe ES, Stein H et al.:A Revised European-American Classification of Lymphoid Neoplasms:A Proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.

• 11) Harris NL, Jaffe ES, Diebold J et al.:The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues:Report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J CIin Oncol 17:3835-3849, 1999

• 12) 菊池昌弘, 大島孝一, 鈴宮淳司:T細胞性リンパ腫のスペクトラムとREAL分類とそれを基にした新WHO分類, 病理と臨床 16:384-389, 1998.

P.33 掲載の参考文献

• 1) 奈良信雄:リンパ節腫脹. 内科診断学. (福井次矢, 奈良信雄・編), 医学書院, 2000, p297.

• 2) 石田 博:発熱. EBM現代内科学. (黒川 清, 斉藤 英彦, 矢崎義雄・編), 金芳堂, 1997, p152.

• 3) Hughes WT, Armstrong D, Bodey GP et al.:From the Infectious Disease Society America. Guidelines for use of antimicrobial agents in neutropenic patients with unexplained fever. J Inf Dis 161:381, 1990.

3 リンパ腫診断学総論

P.41 掲載の参考文献

• 1) 矢田純一:5章7 NK細胞 医科免疫学 改訂6版. 中外医学社, 東京, 1999, p91-96.

• 2) Lanier LL:NK cell receptors. Annu Rev Immunol 16:359-393, 1998.
  pubmed

• 3) Oshimi K, Yamada O, Hattori M et al.:Laboratory findings and clinical courses of 33 patients with granular lymphocyte-proliferative disorders. Leukemia 7:782-788, 1993.
  pubmed

• 4) Harris NL, Jaffe ES, Bloomfield CD et al.:World Health Organization classification of neoplastic disease of the hematopoietic and lymphoid tissues:report of the clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999.
  pubmed

• 5) Stepp SE, Dufourcq-Lagelouse R, Kumar V et al.:Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 286:1957-1959, 1999.

• 6) Baetz K, Isaaz S, Griffiths GM:Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretory defect that prevents lytic granule exoytosis. J Immunol 154:6122-6131, 1995.
  pubmed

• 7) Tonn T, Becker S, Seifried E et al.:Cellular immunotherapy of malignancies using the clonal natural killer cell line nk-92. J Hematother Stem Cell Res 10:535-544, 2001
  pubmed

P.43 掲載の参考文献

• 1) Su IJ, Hsu YH, Lin MT et al.:Epstein-Barr virus-containing T-cell lymphoma presents with hemophagocytic syndrome minicking malignant histiocytosis. Cancer 72 :2019-2027, 1993.

• 2) Falini B, Pileri S, De Solas I et al.:Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood 75:434-444, 1990.
  pubmed

• 3) Inoue Y, Johno M, Matsuoka M:A case of adult T-cell lymphoma leukemia with hemophagocytic syndrome. J Dermatol 27:280-283, 2000.

• 4) Miyahara M, Sano M, Shibata K et al.:B-cell lymphoma-associated hemophagocytic syndrome:clinicopathological characteristics. Ann Hematol 79:378-388, 2000.
  pubmed

• 5) Shimazaki C, Inaba T, Nakagawa M et al.:B-cell lymphoma-associated hemophagocytic syndrome. Leuk Lymphoma 38:121-130, 2000.
  pubmed

P.46 掲載の参考文献

• 1) Teruya-Feldstein J, Jaffe ES, Burd PR et al.:Differential cytokine expression in tissues involved by Hodgkin's disease:direct correlation of eotaxin expression and tissue eosinophilia. Blood 93:2463-2470, 1999.
  pubmed

• 2) Teruya-Feldstein J, Tosato G, Jaffe ES:The role of cytokines in Hodgkin's disease. Leuk Lymphoma 38:363-371, 2000.
  pubmed

P.49 掲載の参考文献

• 1) 山口延男:血球計数. 臨床検査マニュアル. (北村元仕, 三輪史朗, 三輪谷俊夫・他編), 文光堂, 東京, 1988, p325-357.

• 2) Gay JC, Athens JW:Variation of leukocytes in disease. Wintrobe's clinical hematology 10th' ed. (ed. Lee GR, Foerster J, Lukens J, et al.), Lippincott Williams & Wilkins, Baltimore, 1999, p1836-1861.

• 3) Bennett JM, Catovsky D, Daniel MT et al. Proposals for the Classification of Chronic(Mature) B and T Lymphoid Leukemias. J Clin Pathol 42:567-584, 1989.

• 4) Cheson BD, Bennett JM, Rai KR et al.:Guidelines for Clinical Protocols for Chronic Lymphocytic Leukemia:Recommendations of the Natural Cancer Institute-Sponsored Working Group. Am J Hematol 29:152-163, 1988.

• 5) Catovsky D, Foa R:The Lymphoid Leukemias. Butterworth, London, 1990.

• 6) Rozman C, Montserrat E:Chronic Lymphocytic Leukemia. N Engl J Med 333:1052-1057, 1995.
  pubmed

• 7) 待井隆志:Hairy cell leukemia および関連疾患. 病理と臨床 10(1) :31-36, 1992.

• 8) Jaffe ES, Campo E, Raffeld M:Mantle cell lymphoma:Biology and diagnosis. Hematology 1999, The American Society of Hematology Education Program book. (ed. Schechter GP, Hoffman R, Schrier SL et al.), The American Society of Hematology, Washington DC, 1999, p319-324.

• 9) Harris NL, Jaffe ES, Stein H et al.:A Revised European-American Classification of Lymphoid Neoplasms:A Proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.

• 10) 栗山 謙, 外山圭助:悪性リンパ腫とリンパ性白血病の違いは. 臨床医 22:1831-1833, 1996.

• 11) 菊池昌弘, 大島孝一, 鈴宮淳司:T細胞性リンパ腫のスペクトラムとREAL分類とそれを基にした新WHO分類. 病理と臨床 16:384-389, 1998.

P.51 掲載の参考文献

• 1) Rosen FS et al.:Primary immunodeficiency disease:report of a WHO Scientific Group.Clin Exp Immunol 99:1-24, 1995.

• 2) Smith DK, Neal JJ, Holmberg SD:Unexplained opportuistic infections and CD4+ T-lymphocytopenia without HIV infection. An investigation of cases in the United States. N Engl J Med 328:373-379, 1993.
  pubmed

• 3) Ho DD, Neumann AU, Perelson AS et al.:Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1infection. Nature 373:123-126, 1995.

• 4) Noguchi M, Iwamori M, Hirano T et al.:Autoantibodies to T and B cell lines detected in serum samples from patients with systemic lupus erythmatosus with lymphopenia and hypocomplementaemia. Ann Rheum Dis 51:713-716, 1992.

• 5) Laurence J:T-cell subsets in health, infectious disease, and idiopathic CD4+ T lymphocytopenia. Ann Intern Med 119:55-62, 1993.
  pubmed

P.53 掲載の参考文献

• 1) 津田弘之:血球貧食症候群 診断とその問題点. 臨床病理 48:741-745, 2000.

P.55 掲載の参考文献

• 1) Harris NL, Jaffe ES, Stein H et al.:A revised European-American classification of lymphoid neoplasms:a proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.

• 2) Harris NL, Jaffe ES, Diebold J et al.:World Health Organization classification of neoplasms. J Clin Oncol 17:3835-3849, 1999.
  pubmed

• 3) Shimamoto T, Ohyashiki K, Nehashi Y et al.:Leukemic phase of intermediate non-Hodgkin's lymphoma with cells showing different matured stages in invaded various organs. Int Med 31:553-556, 1992.

• 4) Martin AR, Weisenburger DD. Chan WC et al.:Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 85:3671-3678, 1995.
  pubmed

• 5) Uchiyama T, Yodoi J, Sagawa K et al.:Adult T-cell leukemia:Clinical and hematological features of 16 cases. Blood 50:481-485, 1977.

P.58 掲載の参考文献

• 1) Bernier G, Bellanti J:Antibody and Immunoglobulins:Structure and Function. Immunology III:89-105, W. B. Saunders Company, Washington DC, 1985.

• 2) 金井 泉:III 免疫グロブリン, 補体系の検査 臨床検査法提要. 金原出版, 東京, 1998, p818-833.

P.64 掲載の参考文献

• 1) Harris NL, Jaffe ES, Stein H et al.:A Revised European-American Classification of Lymphoid Neoplasms:A Proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.

• 2) Harris NL, Jaffe ES, Diebold J et al.:The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues:Report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999.
  pubmed

• 3) 菊池昌弘, 大島孝一, 鈴宮淳司:T細胞性リンパ腫のスペクトラムとREAL分類とそれを基にした新WHO分類. 病理と臨床 16:384-389, 1998.

• 4) Stewart CC, Stewart SJ:Multi-parameter Analysis of Leukocytes by Flow Cytometry. Methods in Cell Biology. Volume 41. Flow Cytometry 2nd edition. (ed. Darzynkiewicz Z, Robinson Jp, Crissman HA) , Academic Press, San Diego, 1994, p61-80.

• 5) Lewis DE:Cytochemistry I:Cell Surface Immuno-fluorescence. Clinical Flow Cytometry. Principles and Application. (ed. Bauer KD, Douque RE, Shankey TV), Williams & Wilkins, Baltimore, 1993, p143-156.

• 6) Stelzer GT, Shults KE, Loken MR:CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann NY Acad Sci 677:265-280, 1993.
  pubmed

• 7) Lacombe F, Durrieu F, Briais A et al.:Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 11:1878-1886, 1997.
  pubmed

• 8) 右田俊介, 高橋信弘:別冊医学のあゆみ:CD抗原ハンドブック. 医歯薬出版, 東京, 1999.

P.68 掲載の参考文献

• 1) ISCN:An international system for human cytogenetic nomenclature. (ed. Mitelman F), S Karger, Basel, 1995.

• 2) Taniwaki M, Nishida K Ueda Y et al.:Interphase and metaphase detection of the breakpoint of 14q32 translocations in B-cell malignancies by double-color fluorescence in situ hybridization. Blood 85:3223-3228, 1995.

• 3) Greer JP, Macon WR, McCurley TL:Non-Hodgkin lymphomas. (ed. Lee GR, Foerster J, Lukens J, et al.) Wintrobe's Clinical Hematology 10th edition. Williams & Wilkins, Baltimore, 1999, p2447-2537.

• 4) Harris NL, Jaffe ES, Diebold J et al.:The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 10:1419-1432, 1999.
  pubmed

• 5) Willis TG, Dyer MJS:The role of immunoglobulin translocation in the pathogenesis of B-cell malignancies. Blood 96:808-822, 2000.

• 6) Akasaka S, Ueda C, Kurata M et al.:Nonimmunoglobulin (non-Ig) /BCL6 gene fusion in duffuse large B-cell lymphoma results in worse prognosis than Ig/ BCL6. Blood 96:2907-2909, 2000.

P.71 掲載の参考文献

• 1) Lee MS, Chang KS, Cabanillas F et al.:Detection of minimal residual diseasecarrying the t(14;18) by DNA sequence amplification. Science 237:175-178, 1987,

• 2) Cheng S, Fockler C, Barnes WM et al.:Effective amplification of long targets fron cloned inserts and human genomic DNA. Proc Natl Acad Sci USA 91:5695-5699, 1994.

• 3) Akasaka T, Muramatsu M, Ohno H et al.:Application of long distance polymerase chain reaction to detection of junctional sequences created by chromosomal translocation in mature B-cell neoplasms. Blood 88:985-994, 1996.
  pubmed

P.73 掲載の参考文献

• 1) 栗山 謙:実地医家のための癌の臨床ガイド. 悪性リンパ腫. Medical Practice 14:373-384, 1997.

• 2) 押味和夫:リンパ節生検. 臨床医 25:1815-1817, 1999.

• 3) Skarin AT:Approach to the patient with suspected lymphoma. The lymphomas. (ed. Canellos GP, Lister TA, Sklar JL) , W. B. Saunders Company, Philadelphia, 1998, p207-211.

P.76 掲載の参考文献

• 1) Campbell RD, Trowsdale J:Map of the human MHC. Immunol Today 14:349-352, 1993.
  pubmed

• 2) Robinson J, Malik A, Parham P et al. :IMGT/HLA data-base-a sequence database for the human major histocompatibility complex. Tissue antigens 55:280-287, 1999.
  pubmed

• 3) 名古屋骨髄移植グループ:組織適合性の評価. 造血幹細胞移植マニュアル. (小寺良尚, 斎藤英彦・監修), 日本医学館, 1996, p301-312.

4 リンパ腫治療学総論

P.81 掲載の参考文献

• 1) Lister TA, Crowther D, Sutcliffe et al.:Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease:Cotswolds meeting. J Clin Oncol 7:1630, 1989.
  pubmed

• 2) Ng AK, Mauch PM:Radiation therapy in Hodgkin's lymphoma. Semin Hematol 36:290-302, 1999.

• 3) Canellos GP, Anderson JR, Propert KJ et al.:Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP altemating with ABVD. N Engl J Med 19:1478-1484, 1992.
  pubmed

• 4) Laport GF, Williams SF:The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol 25:503-517, 1998.
  pubmed

• 5) Dana BW, Dahlberg S, Nathwani BN et al.:Long-term follow up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemo-immunotherapy. J Clin Oncol 11:644, 1993.
  pubmed

• 6) Fisher RI, Gaynor ER, Dahlberg S et al.:Comparison of astandard regimen(CHOP) with three intensivechemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993.

• 7) Worf M, Matthws Jp, Stone J et al.:Long-term survival advantage of MACOP-B over CHOP in intermediategrade non-Hodgkin's lymphoma. Ann Oncol 8(Suppl 1) :71-75, 1997.

• 8) The International Non-Hodgkin's Lymphoma Prognostic Factor Project:A predictive model for aggressive NHL. N Engl J Med 329:987-994, 1993.

• 9) Shipp MA, Abeloff MD, Antman KH et al.:International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive nonHodgkin's lymphomas:Report of the July. J Clin Oncol 17:423-429, 1999.

P.84 掲載の参考文献

• 1) Sweetenham JW, Carella AM, Taghipour G et al.:High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy:results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 17:3101-3109, 1999.
  pubmed

• 2) Lazarus HM, Rowlings PA, Zhang MJ et al.: Autotransplants for Hodgkin's disease in patients never achieving remission:a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 17:534-545, 1999.
  pubmed

• 3) Andre M, Henry-Amar M, Pico JL et al.:Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure :a case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol 17:222-229, 1999.
  pubmed

• 4) Linch DC, Winfield D, Goldstone AH et al.:Dose inten-sification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease:results of a BNLI randomized trial. Lancet 341:1051-1054, 1993.

• 5) 岡本昌隆:造血幹細胞移植の適応. 臨床血液 42:299-306, 2001.

• 6) Bierman PJ, Vose JM, Anderson JR et al.:High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15:445-450, 1997.
  pubmed

• 7) Freedman AS, Gribben JG, Neuberg D et al.:High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88:2780-2786, 1996.
  pubmed

• 8) van Besien K, Sobocinski KA, Rowlings PA et al.:Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92:1832-1836, 1998.
  pubmed

• 9) Williams CD, Goldstone AH, Pearce RM et al.:Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma:a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 14:2454-2464, 1996.
  pubmed

• 10) Majolino I, Pearce R, Taghipour G et al.:Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas:a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 15:509-517, 1997.

• 11) Stiff PJ, Dahlberg S, Forman SJ et al.:Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma:value of augmented preparative regimens-a Southwest Oncology Group trial. J Clin Oncol 16:48-55, 1998.
  pubmed

• 12) Philip T, Guglielmi C, Hagenbeek A et al.:Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995.
  pubmed

• 13) Haioun C, Lepage E, Gisselbrecht C et al.:Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma:final analysis of the prospective LNH87-2 protocol-a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 18:3025-3030, 2000

• 14) Schmitz N, Linch DC, Dreger P et al.:Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353-357, 1996.
  pubmed

• 15) Chopra R, Goldstone AH, Pearce R et al.:Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma:a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 10:1690-1695, 1992.

• 16) Ratanatharathorn V, Uberti J, Karanes C et al.:Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 84:1050-1055, 1994.
  pubmed

• 17) Brown RA, Adkins D, Khoury H et al.:Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients:graft-versus-host disease and transplant-related mortality. J Clin Oncol 17:806-812, 1999.
  pubmed

P.88 掲載の参考文献

• 1) Tanosaki R, Okamoto S, Akatsuka N et al.:Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma. Cancer 74:1939-1944, 1994.
  pubmed

• 2) Meyer RM, Gyger M, Langley R et al.:A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 30:591-600, 1998.

• 3) American Society of Clinical Oncology:Recommendation for the use of hematopoietic growth factors:Evidence based clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994.

P.90 掲載の参考文献

• 1) McLaughlin P, Grillo-Lopez AJ, Link BK et al.:IDEC C2B8 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:half of patients respond to a four-course treatment program. J Clin Oncol 16:2825-2833, 1998.

• 2) Davis TA, Grillo-Lopez AJ, White CA et al.:Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin lymphoma:safety and effecasy of re-treatment. J Clin Oncol 18:3135-3143, 2000.
  pubmed

• 3) Hainsworth JD, Burris HA, Horrissey LH et al.:Rituximab monoclonal antibody as initial therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95:3052-3056, 2000.

• 4) Czuczman MS, Grillo-Lopez AJ, White CA et al.:Treatment of patients with low grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999.
  pubmed

• 5) Hsu FJ, Benike C, Fagnoni F et al.:Vaccination of patients with B cell lymphoma using autologus antigenpulsed dendritic cells. Nat Med 2:52-58, 1996.

P.95 掲載の参考文献

• 1) Fisher RI, DeVita VT, Young RC et al.:Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 90:761-763, 1979.
  pubmed

• 2) Yuen AR, Rosenberg SA, Horning SJ et al.:Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 89:814-822, 1997.
  pubmed

• 3) Sheehan T, Cuthbert RJ, Parker AC:Central nervous system involvement in haematological malignancies. Clin Lab Haematol 11:331-338, 1989.
  pubmed

• 4) Schumacher M, Orszagh M:Imaging techniques in neoplastic meningiosis. J Neurooncol 38:111-120, 1998.
  pubmed

• 5) 高橋直人, 中鉢明彦, 三浦 亮・他:血球貧食症候群 成人リンパ腫関連血球貧食症候群全国集計からみた臨床病理像(解説) . 臨床血液 40:542-549, 1999.

• 6) 柏木哲夫, 恒藤 暁, 池永昌之・他:緩和ケアマニュアル. 最新医学社, 大阪, 2001.

• 7) Shipp MA, Abeloff MD, Coiffier B et al.:International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas:report of the jury. J Clin Oncol 17:423-429, 1999.

• 8) Ogura M, Kagami Y, Ueda R et al.:Phase I/II trial of cure-oriented high-dose chemoradiotherapy with transplantation of CD34+ peripheral blood stem cells purified by the immunomagnetic bead method for refractory hematological malignancies. Nagoya CD34+ PBSCT Study Group. Cancer Chemother Pharmacol 40 Suppl S51-57, 1997.

• 9) Tarella C, Corradini P, Ferrero D et al.:Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients:evidence for long-term clinical and molecular remissions. Leukemia 13:1456-1462, 1999.
  pubmed

• 10) Buckstein R, Imrie K, Berinstein NL et al.:Stem cell function and engraftment is not affected by"in vivo purging"with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 26(5 Suppl 14) :115-122, 1999.
  pubmed

• 11) Khouri IF, Keating M, Champlin R et al.:Transplant-lite:induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16:2817-2824, 1998.
  pubmed

• 12) 塩原信太郎, 高橋 聡, 小寺良尚・他:Therapeutic effect of donor leukocyte transfusion in relapsing marrow transplants in Japan. 臨床血液 38:1162-1169, 1997.

• 13) Tondini C, Balzarotti M, Bonadonna G et al.:Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma:a phase II randomized study. Ann Oncol 11:231-233, 2000.
  pubmed

• 14) Yoshida M, Maehara Y, Sugimachi K:MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates dox-orubicin-induced acute toxicity while maintaining antitumor efficacy. Clin Cancer Res 5:4295-4300, 1999.

• 15) Borchmann P, Schnell R, Engert A et al.:Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol 12:661-667, 2000.
  pubmed

• 16) Lopes de Menezes DE, Pilarski LM, Allen TM:In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 58:3320-3330, 1998.

• 17) Piro LD, White CA, Jain V et al.:Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10:655-661, 1999.

• 18) Selmayr M, Menzel H, Mocikat R:B-cell lymphoma idiotypes chimerized by gene targeting can induce tumor immunity. Cancer Gene Ther 7:501-506, 2000.
  pubmed

5 リンパ腫各論・疾患編

P.100 掲載の参考文献

• 1) Shipp MA, Mauch PM, Harris NL:Non-Hodgkin's lymphoma Cancer, Principles and practice of oncology. 5th edition. (DeVita VT Jr, Hellman S, RosenbergSA), Lippincott-Raven publishers, Philadelphia, 1997, p1859-1927.

• 2) 堀田知光:悪性リンパ腫(Hodgkin病と非Hodgkinリンパ腫) の標準的治療. 日本内科学会雑誌 90:997-1002, 2001.

• 3) The non-Hodgkin's lymphoma classification project:A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997.

• 4) Harris NL, Jaffe ES, Diebold J et al.:The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues:Report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999.
  pubmed

• 5) Armitage JO:Treatment of non-Hodgkin's lymphoma. N Engl J Med 328:1023-1030, 1993.
  pubmed

• 6) Hiddemann W, Unterhalt M:Current status and future perspectives in the treatment of low-grade non-Hodgkin's lymphoma. Blood Rev 8:225-233, 1994.
  pubmed

• 7) Mac Manus MP, Hoppe RT:Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow up study of patients treated at Stanford university. J Clin Oncol 14:1282-1290, 1996.

• 8) McLaughlin P, Grillo-Lopez AJ, Link BK et al.:Rutuximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998.

• 9) Czuczman MS, Grillo-Lopez AJ, Saleh WM et al.:Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999.

• 10) WitzigTE, White CA, Wiseman GA et al.:Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999.

• 11) Coiffier B, Niedhardt-Berard EM, Tilly H et al.:Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters:A GELA study. Ann Oncol 10:1191-1197, 1999.

• 12) McLaughlin P, Hagemeister FB, Romaguera JE et al.:Fludarabine, mitoxantrone, and dexamathasone:An effective new regimen for indolent lymphoma. J Clin Oncol 14:1262-1268, 1996.

• 13) Crawley CR, Foran JM, Gupta RK et al.:A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. Ann Oncol 11:861-865, 2000.
  pubmed

• 14) McLaughlin P, Hagemeister FB, Rodriguez MA et al.:Safety of fludara-bine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 27(6 suppl 12) :37-41, 2000.

• 15) Boussiotis VA, Freedman AS, Nadler LM:Bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Semin Hematol 36:209-216, 1999.
  pubmed

• 16) Buckstein R, Imrie K, Spaner D et al.:Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 26(5 suppl 14) :115-122, 1999.

• 17) Bayerdorffer E, Neubauer A, Rudolph B et al.:Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobactor pylori infection. Lancet 345:1591-1594, 1995.

• 18) The European Helicobactor Pylori Study Group:Current European concepts in the management of Helicobactor pylori infection. The Maastricht consensus report. Gut 41:8-13, 1997.

• 19) Isaacson PG:Mucosa-associated lymphoid tissue lymphoma. Semin Hematol 36:139-147, 1999.
  pubmed

• 20) 飛内賢正:低悪性度Bリンパ腫の治療戦略. 臨床血液 42 :288-292, 2000

• 21) Coiffier C, Thieblemont C, Felman P et al.:Indolent nonfollicular lymphomas:characteristics, treatment, and outcome. Semin Oncol 36:198-208, 1999.

• 22) Thieblemont C, Berger F, Dumontel C et al.:Mucosaassociated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 95:802-806, 2000.

• 23) Troussard X, Valensi F, Duchayne E et al.:Splenic lymphoma with villous lymphocytes:clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol 93:731-736, 1996.

• 24) Berger F, Felman P, Thieblemont C et al.:Non-MALT marginal zone lymphomas:a description of clinical presentation and outcome in 124 patients. Blood 95:1950-1956, 2000.
  pubmed

• 25) Hermans J, Krol AD, van Groningen K et al.:Internatinal prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 86:1460-1463, 1995.

P.105 掲載の参考文献

• 1) The Non-Hodgkin's Lymphoma Pathologic Classification Project:National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas:Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982.

• 2) Hiddemann W, Longo DL, Coiffier B et al.:Lymphoma classification-The gap between biology and clinical management is closing. Blood 88:4085-4089, 1996.
  pubmed

• 3) The Non-Hodgkin's Lymphoma Classification Project:A clinical evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997.

• 4) Willis TG, Dyer MJS:The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 96:808-822, 2000.

• 5) The International Non-Hodgkin's Lymphoma Prognostic Factors Project:A predictive model for agressive NHL:The International Non-Hodgkin's Lymphoma Prognostic Factor Project. N Engl J Med 329:987-994, 1993.

• 6) Miller TP, Dahlberg S, Cassady JR et al.:Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-intermediate grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998.
  pubmed

• 7) Fisher RI, Gaynor ER, Dahlberg S et al.:Comparison of a standard regimen(CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993.
  pubmed

• 8) Shipp MA, Abeloff MD, Antman KH et al.:International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphoas. J Clin Oncol 17:423-429, 1999.

• 9) Vose JM, Link BK, Grossbard ML et al.:Phase II study of rituximab in combination with CHOP chemotheray in patients with previously untreatd, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19:389-397, 2001.

• 10) Alizadeh AA, Eisen MB, Davis RE et al.:Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000.
  pubmed

P.110 掲載の参考文献

• 1) 飛内賢正:予後推測および治療選択指針としてのリンパ腫病期分類. 血液・腫瘍科 37:405-414, 1998.

• 2) Fisher RI, Grogan TM, Dahlberg S et al:Clinical behavior of 2, 168patients treated on Southwest Oncology Group (SWOG) protocols and reclassified according to the R. E. A. L. classification. Ann Oncol 7 (Suppl 3) :3, 1996.

• 3) Shipp MA, Mauchi PM, Harris NL. Non-Hodgkin's lymphoma. In Cancer:Principles and Practice of Oncology, 5th. (ed. DeVita VTJr et al. ), Lippincott-Raven, Philadelphia, PA, 1997, p2165.

• 4) Hiddemann W, Longo DC, Coiffier B et al.:Lymphoma Classification:The gap between biology and clinical management is closing. Blood 88:4085-4089, 1996.

• 5) The Non-Hodgkin's Lymphoma Classification Project:A clinical evaluation of the International Lymphoma Study Group Classification of the non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997.

• 6) 下山正徳, 向井 清, 菊池昌弘・他:専門病理医の中央診断をうけた非ホジキンリンパ腫447例の重要な予後因子と予後予測に有用な臨床病理予後分類 (Lymphoma Clinico-pathological Prognostic Classification:LCP分類) とLCPスキーマ. 日本リンパ網内系学会誌 38:41, 1998.

• 7) 熊谷匡也, 高木俊之:悪性リンパ腫の治療戦略3:中高悪性度非ホジキンリンパ腫. 治療学 34:838-842, 2000.

• 8) 木下朝博:高悪性度リンパ腫. 悪性リンパ腫治療マニュアル. (平野正美, 飛内賢正・編), 南江堂, 東京, 1998, p67-73.

• 9) Levine AM, Forman SJ, Meyer PR et al.:Successful therapy of convoluted T-lymphoblastic lymphoma in the adult. Blood 61:92-98, 1983.
  pubmed

• 10) Slater DE, Mertelsmann R, Koziner B et al.:Lymphoblastic lymphoma in adults. J Clin Oncol 4:57-67, 1986.
  pubmed

• 11) Coleman CN, Picozzi VJ Jr, Cox RS et al.:Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 4:1628-1537, 1986.
  pubmed

• 12) Sweetenham JW, Liberti G, Pearce R et al.:High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma:results of the European group for bone marrow transplantation. J Clin Oncol 12 :1358-1365, 1994.

P.113 掲載の参考文献

• 1) Stein H, Mason DY, Gerdes J et al.:The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue:evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848-858, 1985.
  pubmed

• 2) Harris NL, Jaffe ES, Stein H et al.:A Revised European-American Classification of Lymphoid Neoplasms:a proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.

• 3) Harris NL, Jaffe ES, Diebold J et al.:World Health Organization classification of neoplasms. J Clin Oncol 17:3835-3849, 1999.
  pubmed

• 4) Moris SW, Kirstein MN, Valentine MB et al.:Fusion of a kinase gene. ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263:1281-1284, 1994.

• 5) Shiota M, Fujimoto J, Semba T et al.:Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9:1567-1574, 1994.

• 6) Shiota M, Nakamura S, Ichinohasama R et al.:Anaplastic large cell lymphomas expressing the novel chimeric protein p80 NPM/ALK:a distinct clinicopathologic entity. Blood 86:1954-1960, 1995.

• 7) Fanin R, Silvestri F, Geromin A et al.:Primary systemic CD30(Ki-1) -positive anaplastic large cell lymphoma of the adult:sequential intensive treatment with the F-MACHOP regimen(+/- radiotherapy) and autologous bone marrow transplantation. Blood 87:1243-1248, 1996.

• 8) Zinzani PL, Matelli M, Magagnoli M et al.:Anaplastic large cell lymphoma Hodgkin's-like:a randomized trial of ABVD versus MACOP-B with and without radiation therapy. Blood 92:790-794, 1998.

P.116 掲載の参考文献

• 1) Rohatiner A, d'Amore F, Coiffier B et al.:Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 5:397-400, 1994.

• 2) 高木敏之:節外病変の臨床的特徴. 臨床血液 40:188-191, 1999.

• 3) 小西 博:節外性リンパ腫(脳リンパ腫). 悪性リンパ腫治療マニュアル. (平野正美. 飛内賢正・編) , 南江堂, 1998, p103-106.

• 4) Hiddemann W, Unterhalt M:Current status and future porspectives in the treatment of low-grade non-Hodgkin's lymphomas. Blood Reviews 225-233, 1994.

• 5) Miller TP, Dahlberg S, Cassady JR et al.:Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. Engl J Med 339:21-26, 1998.

• 6) Freilich RJ, DeAngelis LM:Primary central nervous system lymphoma. Neurol Clin 13:901-914, 1995.
  pubmed

• 7) Smitt MC, Donaldson SS:Radiotherapy is successful treatment for orbital lymphoma. Int J Radiat Oncol Biol Phys 26:59-66, 1993.
  pubmed

• 8) Chao CK, Lin HS, Devineni VR et al.:Radiation therapy for primary orbital lymphoma. J Radiat Oncol Biol Phys 31:929 934, 1995.

• 9) 大川智彦, 唐澤久美子, 兼安祐子:悪性リンパ腫の放射線療法の位置づけ. 臨床医 25:1912-1914, 1999.

• 10) Connor JM:Problems in Lymphoma Management:Special Sites of Presentation. Oncology 12:185-195, 1998.

• 11) Peterson K, Gordon KB, Heinemann MH et al.:The clinical spectrum of ocular lymphoma. Cancer 72:843-849, 1993
  pubmed

• 12) Kwong YL, Chan AC, Liang R et al.:CD56＋NK ｌymphomas:clinicopathological features and prognosis. Br J Haematol 97:821-829, 1997.
  pubmed

• 13) Cheung MM, Chan JK, Lau WH et al.:Primary non-Hodgkin's lymphoma of the nose and nasopharynx:clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 16:70-77, 1998.
  pubmed

• 14) Liang R, Chen F, Lee CK et al:Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma. Bone Marrow Transplant 19:91-93, 1997.

• 15) Doria R, Jekel JF, Cooper DL:Thyroid lymphoma. The case for combined modality therapy. Cancer 73:200-206, 1994.
  pubmed

• 16) 重岡 靖, 伊藤国昭, 大津智子:胃リンパ腫の治療方針. 日本内科学会雑誌 90:1003-1009, 2001.

• 17) Koch P, Grothaus-Pinke B, Hiddemann W et al.:Primary lymphoma of the stomach:three-year results of a prospective multicenter study. The German Multicenter Study Group on GI-NHL. Ann Oncol 8:85-88, 1997.

• 18) Harris NL, Jaffe ES, Diebold J et al.:World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues;report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November. J Clin Oncol 17:3835-3849, 1999.

P.120 掲載の参考文献

• 1) Suzumiya J, Takeshita M, Kimura N et al.:Sinonasal malignant lymphoma of natural killer cell phenotype associated with diffuse pancreatic involvement. Leuk Lymphoma 10:231-236, 1993.
  pubmed

• 2) Suzumiya J, Takeshita M, Kimura N, et al.:Expression of adult and fetal natural killer cell markers in sinonasal lymphomas. Blood 15:83:2255-2260, 1994.

• 3) 鈴宮淳司, 田村和夫, 大島孝一:NK細胞リンパ腫の 臨床病態. 血液・腫瘍科 42:319-324, 2001.

• 4) The world health organization classification of malignant lymphomas in Japan:Incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 50:696-702, 2000.

• 5) Suzumiya J, Ohshima K, Takeshita M et al.:Nasal lymphomas in Japan:a high prevalence of Epstein-Barr virus type A and deletion within the latent membrane protein gene. Leuk Lymphoma 35:567-578, 1999.
  pubmed

• 6) Ohshima K, Suzumiya J, Kanda M et al.:lntegrated and episomal forms of Epstein-Barr virus(EBV) in EBV associated disease. Cancer Lett 9 (122) 43-50, 1998.

• 7) Wong KF, Zhang YM, Chan JK:Cytogenetic abnormalities in natural killer cell lymphoma / leukaemia-is there a consistent pattern? Leuk Lymphoma 34:241-250, 1999.

• 8) 菊池昌弘, 鈴宮淳司:鼻および鼻腔NK/T細胞リンパ腫. 新悪性リンパ腫アトラス. (須知泰弘, 菊池昌弘・編) , 文光堂, 東京, 2000.

• 9) Cheung MM, Chan JK, Lau WH et al.:Primary non-Hodgkin's lymphoma of the nose and nasopharynx:clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 16:70-77, 1998.
  pubmed

• 10) Kim WS, Song SY, Ahn YC et al.:CHOP followed by involved field radiation:is it optimal for localized nasal natural killer/ T-cell lymphoma? Ann Oncol 12:349-352, 2001.
  pubmed

• 11) Sasaki M, Matsue K, Takeuchi M et al.:Successful treatment of disseminated nasal NK/T-cell lymphoma using double autologous peripheral blood stem cell transplantation. Int J Hematol 71:75-78, 2000.
  pubmed

• 12) Rodriguez J, Romaguera JE, Manning J et al.:Nasaltype T/ NK lymphomas:a clinicopathologic study of 13 cases. Leuk Lymphoma 39:139-144, 2000.

P.123 掲載の参考文献

• 1) Magrath IT, Bhatia K:Pathogenesis of small non cleaved cell lymphoma(Burkitt's lymphoma) . In The non-Hodgkin's Lymphoma, 2nd ed. (ed. by Magrath I) . Arnold, London, 1997, pp385-410.

• 2) Shiramizu B, Barriga F, Neequaye J et al.:Patterns of chromosomal break point location in Burkitt's lymphoma:Relevance to geography and EBV association. Blood 77:1516-1526, 1991.

• 3) Magrath IT, Jain V, Bhatia K:Epstein Barr virus and Burkitt's lymphoma. Semin. Cancer Biol 3:285-295, 1992.

• 4) Harris N, Jaffe ES, Stein H:A proposal for an international consensus on the classification of lymphoid neoplasm. Blood 84:1361-1392, 1994.

• 5) Magrath IT, Adde M, Shad A et al.:Adults and children with small non-cleaved cell lymphoma have a simillar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 3:925-934, 1996.

• 6) Lopez TM, Hagemeister FB, McLaughlin P et al.:Small non-cleaved cell lymphoma in adults:Supeior results for stage I-III. J Clin Oncol 8:615-622, 1990.

• 7) Soussain C, Patte C, Ostronoff M et al.:Small non-cleaved cell lymphoma and leukemia in adults. A respective study of 65 adults treated with the LMB pediatric protocol. Blood 85:664-674, 1995.

P.125 掲載の参考文献

• 1) Harris NL, Jaffe ES, Diebold J et al.:The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues:Report of the clinical advisory committee meeting-Airlie House, Virginia November, 1997. J Clin Oncol 17:3835-3849, 1999.
  pubmed

• 2) Isaacson PG, Wright DH:Malignant lymphoma of mucosa-associated tissue:a distinctive type of B-cell lymphoma. Cancer 52:1410-1416, 1983.

• 3) Isaacson PG, Spencer J:Malignant lymphoma of mucosa-associated lymphoid tissue. Histopathology 11:445-462, 1987.
  pubmed

• 4) Isaascon PG:Mucosa-associated lymphoid tissue lymphoma. Semin Hematol 36:139-147, 1999.

• 5) Harris NL, Isaacson PG:What are the criteria for distinguishing MALT from non-MALT lymphoma at extranodal sites? Am J Clin Pathol 111:S126-S132, 1999.
  pubmed

• 6) Bayerdorffer E, Neubauer A, Rudolph B et al.:Regression of primary gastric lymphoma of mucosaassociated lymphoid tissue type after cure of Helicobactor pylori infection. Lancet 345:1591-1594, 1995.

• 7) The European. Helicobactor Pylori Study Group:Current European concepts in the management of Helicobactor pylori infection. The Maastricht consensus report. Gut 41:8-13, 1997.

• 8) Coiffier C, Thieblemont C, Felman P et al.:Indolent nonfollicular lymphomas:characteristics, treatment, and outcome. Semin Oncol 36:198-208, 1999.

• 9) Thieblemont C, Berger F, Dumontel C et al.:Mucosaassociated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 95:802-806, 2000.

• 10) 飛内賢正:低悪性度Bリンパ腫の治療戦略. 臨床血液 42:287-288, 2000.

• 11) Shipp MA, Mauch PM, Harris NL:Non-Hodgkin's lymphoma. Cancer Principles and practice of oncology. 5th edition. (ed. DeVita VT Jr, Hellman S, Rosenberg SA) , Lippincott-Raven publishers, Philadelphia, 1997, p1859-1927.

P.129 掲載の参考文献

• 1) Harris NL, Jaffe ES, Diebold J et al.:The World Health Organization classification of hematological malignancies report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997. Mod Pathol 13:193-207, 2000.
  pubmed

• 2) Harris NL, Jaffe ES, Stein H et al.:A revised European-American classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.

• 3) Weisenburger DD, Armitage JO:Mantle cell lymphoma:An entity comes of age. Blood 87:4483-4494, 1996.
  pubmed

• 4) The Non-Hodgkin's Lymphoma Classification Project:A clinical evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma. Blood 89:3909-3918, 1997.

• 5) Banks PM et al.:Mantle cell lymphoma:A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 16:637-640, 1992.
  pubmed

• 6) Ott G, Kalla J, Ott MM et al.:Blastoid variants of mantle cell lymphoma:Frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 89:1421-1429, 1997.
  pubmed

• 7) Rimokh R, Berger F, Delsol G et al.:Rearrangement and overexpression of the bcl-1/ PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11;q13)-bearing leukemias. Blood 81:3063-3067, 1993.

• 8) Greiner TC, Moynihan MJ, Chan WC et al.:p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87:4302-4310, 1996.
  pubmed

• 9) Fisher RI, Dahlberg S, Nathwani BN et al.:A clinical analysis of two indolent lymphoma entities:mantle cell lymphoma and marginal zone lymphoma(including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories) :A Southwest Oncology Group Study. Blood 85:1075-1082, 1995.

• 10) Yatabe Y, Suzuki R, Tobinai K et al.:Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma:a clinicopathologic comparison of cyclin D1-positive MCL and clyclin D1-negative MCL-like B-cell lymphoma. Blood 95:2253-2261, 2000.

P.137 掲載の参考文献

• 1) Harris NL, Jaffe ES, Diebold J et al.:World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues:report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999.
  pubmed

• 2) Mueller N, Evans A, Harris NL et al.:Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med 320:689-695, 1989.
  pubmed

• 3) Serraino D, Franceschi S, Talamini R et al.:Socio-economic indicators, infectious diseases and Hodgkin's disease. Int J Cancer 47:352-357, 1991.
  pubmed

• 4) Tomita Y, Ohsawa M, Kanno H et al.:Epstein-Barr virus in Hodgkin's disease patients in Japan. Cancer 77:186-192, 1996.
  pubmed

• 5) Epstein AL, Marder RJ, Winter JN et al.:Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors. J Immunol 133:1028-1036, 1984.

• 6) Mori N, Oka K, Sakuma H et al.:Immunoelectron microscopic study of Hodgkin's disease. Cancer 56:2605-2611, 1985.
  pubmed

• 7) Stein H, Mason DY, Gerdes J et al.:The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue:evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848-858, 1985.
  pubmed

• 8) Tamaru J, Hummel M, Zemlin M et al.:Hodgkin's disease with a B-cell phenotype often shows a VDJ rearrangement and somatic mutations in the VH genes. Blood 84:708-715, 1994.

• 9) Hummel M, Marafioti T, Ziemann K et al.:Ig rearrangements in isolated Reed-Sternberg cells:conclusions from four different studies. Ann Oncol 4(Suppl) :31-33, 1996.

• 10) Aizawa S, Nakano H, Ishida T et al.:Tumor necrosis factor receptor-associated factor(TRAF) 5 and TRAF2 are involved in CD30-mediated NF kappa B activation. J Biol Chem 272:2042-2045, 1997.
  pubmed

• 11) Duckett CS, Gedrich RW, Gilfillan MC et al.:Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol 17:1535-1542, 1997.
  pubmed

• 12) Bargou RC, Emmerich F, Krappmann D et al.:Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 100:2961-2969, 1997.

• 13) Baldwin AS Jr:The NF-kappa B and I kappa B proteins:new discoveries and insights. Annu Rev Immunol 14:649-683, 1996.
  pubmed

• 14) Emmerich F, Meiser M, Hummel M et al.:Overexpression of I Kappa B Alpha Without Inhibition of NF-B Activity and Mutations in the I Kappa B Alpha Gene in Reed-Stemberg Cells. Blood 94:3129-3134, 1999.

• 15) Gruss HJ, Pinto A, Duyster J et al.:Hodgkin's disease:a tumor with disturbed immunological pathways. Immunol Today 18:156-163, 1997.
  pubmed

• 16) May MJ, Ghosh S:Signal transduction through NF-kappa B. Immunol Today 19:80-88, 1998.

• 17) Hsu PL, Hsu SM:Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells:distinction between Hodgkin's disease and anaplastic large cell lymphoma. Lab Invest 80:1111-1119, 2000.
  pubmed

• 18) Kim SH, Shin YK, Lee IS et al.:Viral latent membrane protein 1(LMP-1) -induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype. Blood 95:294-300, 2000.

• 19) Huen DS, Henderson SA, Croom-Carter D et al.:The Epstein-Barr virus latent membrane protein-1(LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10:549-560, 1995.
  pubmed

• 20) Kapp U, Yeh WC, Patterson B et al.:Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 189:1939-1946, 1999.
  pubmed

• 21) Tubiana M, Henry-Amar M, Carde P et al.:Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials:1964-1987. Blood 73:47-56, 1989.
  pubmed

• 22) Ng AK, Mauch PM:Radiation therapy in Hodgkin's lymphoma. Semin Hematol 36:290-302, 1999.

• 23) Specht L, Gray RG, Clarke MJ et al.:Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease:a meta-analysis of 23 randomized trials involving 3, 888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 16:830-843, 1998.

• 24) Wirth A, Chao M, Corry J et al.:Mantle irradiation alone for clinical stage I-II Hodgkin's disease:long-term follow-up and analysis of prognostic factors in 261 patients. J Clin Oncol 17:230-240, 1999.

• 25) Gobbi PG, Pieresca C, Frassoldati A et al.:Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients:the Gruppo Italiano per lo Studio dei Linfomi Experience. J Clin Oncol 14:527-533, 1996.

• 26) Ng AK, Weeks JC, Mauch PM et al.:Laparotomy versus no laparotomy in the management of early-stage, favor able-prognosis Hodgkin's disease:a decision analysis. J Clin Oncol 17:241-252, 1999.

• 27) Horning SJ, Hoppe RT, Mason J et al.:Stanford-Kaiser Permanente G1 study for clinical stage I to II A Hodgkin's disease:subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 15:1736-1744, 1997.

• 28) Canellos GP, Anderson JR, Propert KJ et al.:Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992.
  pubmed

• 29) Bonadonna G, Santoro A, Gianni AM et al.:Primary and salvage chemotherapy in advanced Hodgkin's disease:the Milan Cancer Institute experience. Ann Oncol 1(Suppl) :9-16, 1991.

• 30) Loeffler M, Brosteanu O, Hasenclever D et al.:Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 16:818-829, 1998.

• 31) Takenaka T, Mikuni C, Miura A et al.:Altemating combination chemotherapy C-MOPP(cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease:a multicenter phase II study(JCOG 8905) . The Lymphoma Study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol 30:146-152, 2000.

• 32) Ferme C, Sebban C, Hennequin C et al.:Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease:results of the Groupe d'etudes des Lymphomes de l'Adulte H89 trial. Blood 95:2246-2252, 2000.
  pubmed

• 33) Shin MS, Ho KJ:Diffuse thymic hyperplasia following chemotherapy for nodular sclerosing Hodgkin's disease. An immunologic rebound phenomenon? Cancer 51:30-33, 1983.
  pubmed

• 34) Horning SJ, Rosenberg SA, Hoppe RT et al.:Brief chemotherapy(Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease:an update. Ann Oncol 4 (Suppl) :105-108, 1996.

• 35) Diehl V, Franklin J, Hasenclever D et al.:BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma:interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 16:3810-3821, 1998.

• 36) Santoro A, Viviani S, Villarreal CJ et al.:Salvage chemotherapy in Hodgkin's disease irradiation failures:superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 70:343-348, 1986.
  pubmed

• 37) Hartmann F, Renner C, Jung W et al.:Treatment of Refractory Hodgkin's Disease With an Anti-CD16/ CD30 Bispecific Antibody. Blood 89:2042-2047, 1997.
  pubmed

• 38) Yuen AR, Rosenberg SA, Hoppe RT et al.:Comparison between Conventional Salvage Therapy and High-Dose Therapy with Autografting for Recurrent or Refractory Hodgkin's Disease. Blood 89:814-822, 1997.
  pubmed

• 39) Linch DC, Winfield D, Goldstone AH et al.:Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease:results of a BNLI randomised trial. Lancet 341:1051-1054, 1993.
  pubmed

• 40) Andre M, Henry-Amar M, Pico JL et al.:Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure:a case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol 17:222-229, 1999.
  pubmed

• 41) Sweetenham JW, Carella AM, Taghipour G et al.:High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy:results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 17:3101-3109, 1999.
  pubmed

• 42) Laport GF, Williams SF:The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol 25:503-517, 1998.
  pubmed

• 43) Pfreundschuh MG, Rueffer U, Lathan B et al.:Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens:a trial of the German Hodgkin's Disease Study Group. J Clin Oncol 12:580-586, 1994.

• 44) Gianni AM, Siena S, Bregni M et al.:High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease-a6-year update. Ann Oncol 4:889-891, 1993.
  pubmed

• 45) Rodriguez J, Rodriguez MA, Fayad L et al.:ASHAP:A Regimen for Cytoreduction of Refractory or Recurrent Hodgkin's Disease. Blood 93:3632-3636, 1999.
  pubmed

• 46) Hoppe RT:Hodgkin's disease:complications of therapy and excess mortality. Ann Oncol 1(Suppl) :115-118, 1997.

• 47) Tucker MA, Coleman CN, Cox RS et al.:Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318:76-81, 1988.
  pubmed

P.144 掲載の参考文献

• 1) Rozman C, Montserrat E:Current concepts:Chronic lymphocytic leukemia. N Engl J Med 333:1052-1057, 1995.

• 2) Rai KR et al.:Clinical Staging of chronic lymphocytic leukemia. Blood 46:219-234, 1975.
  pubmed

• 3) Binet JL, Auruier A, Dighiero G et al.:A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198-206, 1981.
  pubmed

• 4) Cheson BD, Bennet JM, Grever M et al.:National Cancer Institute-sponsored Working Group guidelined for chronic lymphocytic leukemia:Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996.

P.146 掲載の参考文献

• 1) Korsmeyer SJ, Greene WC, Cossman J et al.:Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sci 80:4522-4526, 1983.
  pubmed

• 2) Robbins BA, Ellison DJ, Spinosa JC et al.:Diagnostic application of of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 82:1277-1287, 1993.
  pubmed

• 3) Sainati L, Matutes E, Mulligan S et al.:A variant form of hairy cell leukemia resistant to alpha-interferon:clinical and phenotypic characteristics. Blood 76:157-162, 1990.

• 4) Yamaguchi M, Machii T, Shibayama H et al.: Immunophenotypic features and configuration of immunoglobulin genes in hairy cell leukemia-Japanese variant. Leukemia 10:1390-1394, 1996.
  pubmed

• 5) Ratain MJ, Golomb HM, Vardiman JW et al.:Treatment of hairy cell leukemia with recombinant alpha 2 interferon. Blood 65:644, 1985.
  pubmed

• 6) Grever M, Kopecky K, Foucar MK et al.:Randamized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia:an intergroup study. J Clin Oncol 13:974-982, 1995.

• 7) Saven A, Piro L:Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med 330:691-697, 1990.

P.150 掲載の参考文献

• 1) Yamada Y, Tomonaga M, Fukuda H et al.:A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukemia-lymphoma(ATL) . Japan Clinical Oncology Group (JCOG) Study. 9303. Br J Haematol 113 :375-382, 2001.

• 2) 山田恭暉:高悪性度リンパ腫(成人T細胞白血病) . 臨床血液 42:293-298, 2001.

• 3) 山田恭暉:成人T細胞白血病. 血液疾患マニュアル. 日本医師会, 東京, 2000, p200-203.

• 4) 森 茂久:日本人の偉大な発見-成人T細胞白血病-. 血液疾患のとらえかた. 文光堂, 東京, 2001, p160-166.

• 5) 高月 清, 松崎博充, 松岡雅雄:成人T細胞白血病・リンパ腫瘍の治療. 日本内科学会雑誌 83:928-932, 1994.

P.152 掲載の参考文献

• 1) Castleman B, Iverson L, Menendez VP:Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 9:822-830, 1956.

• 2) Keller AR, Hochholzer L, Castleman B:Hyaline-vascular and plasma cell types of giant lymph-node hyperplasia of the mediastinum and other locations. Cancer 29:670-683, 1972.
  pubmed

• 3) Leibetseder. F, Thurner J:Angiofolli kurale lymphoknotenhyperplasie. Medizinische Klinic 68:817-820, 1973.

• 4) Frizzera G:Castleman's disease and related disorders. Semin in Diagn Pathol 5:346-364, 1988.

• 5) Brandt SJ, Bodine DM, Dunbar CE et al.:Dysregulated interleukin-6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 86:592-599, 1990.

• 6) Yoshizaki K, Matsuda T, Nishimoto N et al.:Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74:1360-1367, 1989.

• 7) Beck JT, Hsu SM, Wijdenes J et al.:Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 330:602-605, 1994.

• 8) Nishimoto N, Shima Y, Sasai M et al.:Clinical application of interleukin-6 receptor antibody. 臨床血液 20:87-94, 1997.

• 9) 中西孝雄:Crow-Fukase症候群について. 臨床神経 29:1477-1484, 1989.

P.155 掲載の参考文献

• 1) 小林信一, 立澤 宰:伝染性単核症. 領域別症候群シリーズ 25:145-147, 1999.

• 2) 加藤卓司, 松田信義:Infectious Mononucleosis症候群の臨床・検査値の相互関連. 臨床病理 46:1056-1060, 1998.
  Medical*Online

• 3) Schwarzmann F, Jager M, Homef M, et al.:Epstein-Barr viral gene expression in B-lymphocytes. Leuk Lymphoma 30:123-129, 1998.

• 4) 森 茂郎, 片野春隆:EBV関連リンパ腫. 日本臨床 55:391-393, 1997.

• 5) Huemer HP, Larcher C, Prodinger WM et al.:Detemination of soluble CD21 as a parameter of B cell activation. Clin Exp immunol 93:195-199, 1993.

P.158 掲載の参考文献

• 1) Imashuku S:Differential diagnosis of hemophagocytic syndrome:underlying disorders and selection of the most effective treatment. Int J Hematol 66:135-151, 1997.
  pubmed

• 2) 河 敬世:血球貧食症候群Hemophagocytic Syndrome. 日本リンパ網内系学会誌 37:145-153, 1997.

• 3) Murase T, Nakamura S, Kawauchi K et al.:An Asian variant of intravascular large B-cell lymphoma:clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol 111:826-834, 2000.

• 4) Henter J, Elinder G, Ost A et al.:Diagnostic guidline for hemophagocytic lymphohistiocytosis. Semin Oncol 18:29-33, 1991.

• 5) 今宿晋作:血球貧食症候群をどう診断するか? 日常診療と血液 7:1043-1050, 1997.

• 6) Chen JS, Tzeng CC, Tsao CJ et al.:Clonal karyotype abnormalities in EBV-associated hemophagocytic synrome. Haematologica 82:572-576, 1997.

• 7) Shimazaki C, Inaba T, Shimura K et al.:B-cell lym-phoma associated with haemophagocytic syndrome:a clinical, immunological and cytogenetic study. Br J Haematol 104:672-679, 1999.

• 8) Ohga S, Nomura A, Kai T et al.:Prolonged resolution of hemophagocytic lymphohistiocytosis following myeloablative chemotherapy and subsequent autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 19:633-635, 1997.

• 9) 高橋直人, 中鉢明彦, 三浦偉久男・他:本邦における成人リンパ腫関連血球貧食症候群. 臨床血液 40:542-549, 1999.

P.161 掲載の参考文献

• 1) Scott RB, Robb-Smith AHT:Histiocytic medullary reticulosis. Lancet 2:194-198, 1939.

• 2) Rappaport H:Tumors of the hematopoietic systems. In:Atlas of Tumor Pathology, 49-63, Armed Forces Institutes of Pathology, Washington DC, 1966.

• 3) Egeler RM, Schmitz L, Sonneveld P et al.:Malignant histiocytosis:a reassessment of cases formerly classified as histiocytic neoplasms and review of the literature. Med Pediatr Oncol 25:1-7, 1995.
  pubmed

• 4) Kobari S, Ohshima K, Sumiyoshi Y et al.:Analysis of the Epstein-Barr virus genome in so-called malignant histiocytosis syndrome. Pathol Int 46:355-363, 1996.
  pubmed

• 5) Su IJ, Hsu YH, Lin MT et al.:Epstein-Barr virus-containing T-cell lymphoma presents with hemophagocytic syndrome mimicking malignant histiocytosis. Cancer 72 :2019-2027, 1993.
  pubmed

• 6) Jaffe ES, Chan JK, Su IJ et al.:Report of the workshop on nasal and related extranodal angio centric T/natural killer cell lymphomas:Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 20:103-111, 1996.

• 7) Kikuta H, Sakiyama Y, Matsumoto S et al.:Fatal Epstein Barr virus-associated hemophagocytic syndrome. Blood 82:3259-3264, 1993.
  pubmed

• 8) Dolezal MV, Kamel OW, Van de Rijn M et al.:Virus-associated hemophagocytic syndrome characterized by clonal Epstein-Barr virus genome. Am J Clin Pathol 103:189-194, 1995.
  pubmed

• 9) Sonneveld P, van Lom K, Kappers-Klunne M et al.:Clinicopathological diagnosis and treatment of malignant histiocytosis. Br J Haematol 75:511-516, 1990.
  pubmed

• 10) Hsu S, Ho Y, Hsu P:Lymphomas of true histiocytic origin. Expression of different phenotypes in so-called true histiocytic lymphoma and malignant histiocytosis. Am J Pathol 138:1389-1404, 1991.
  pubmed

P.163 掲載の参考文献

• 1) Waldenstrom JG:Incipient myelomatosis or "essential" hyperglobulinemia with fibrinogenopenia-A new syndrome? Acta Med Scand 117:216-247, 1944.

• 2) Dimopoulos MA, Alexanian R:Waldenstrom's macroglobulinemia. Blood 83:1452-1459, 1994.

• 3) Harris NL, Jaffe ES, Stein H et al.:A revised European-American classification of lymphoid neoplasms:a proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.

• 4) Waldenstrom JG:Macroglobulinemia-A review. Haematologica 71:437-440, 1986.
  pubmed

• 5) Diebold J, Molina T, Tissier F et al.:Waldenstrom's macroglobulinemia is a biological syndrome which may occur during the evolution of different types of low grade B cell lymphoma. Leukemia 13:1637-1638, 1999.

• 6) Kuriyama Y, Uchida Y, Yaguchi M et al.:Disparity between the macroglobulin-producing components of two cases of follicular lymphoma with Waldenstrom's macroglobulinemia. lnt J Hematol 74:193-196, 2001.

• 7) MacKenzie MR, Fundenberg HH:Macroglobulinemia:an analysis for forty patients. Blood 39:874-889, 1972.

• 8) Waldenstrom JG:Macroglobulinemia. Adv Metab Dis 2:115-118, 1965.

• 9) Coiffier C, Thieblemont C, Felman P et al.:Indolent nonfollicular lymphomas:characteristics, treatment, and outcome. Semin Oncol 36:198-208, 1999.

• 10) Gertz MA, Fonseca R, Rajkumar V:Waldenstrom's macroglobulinemia. The Oncologist 5:63-67, 2000.

• 11) Foran JM, Rohatiner AZS, Coiffier B et al.:Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 17:546, 1999.

P.166 掲載の参考文献

• 1) 森 茂郎, 小池盛雄, 前田義治・他:エイズと悪性リンパ腫. エイズジャーナル 2:119-124, 1989.

• 2) 高田 昇, 川野宏則, 藤井輝久・他:エイズにみられる悪性腫瘍-悪性リンパ腫とカポジ肉腫-. Modern Physician 13:1267-1270, 1993.

• 3) Liebowitz D:Epstein-Barr virus and a cellular signaling pathway in lymphoma from immunosuppressed patients. N Engl J Med 338:1413-1421, 1998.

• 4) 片野晴盛, 森 茂郎:日和見腫瘍. 細胞工学 15:1258-1266, 1996.

• 5) 中村哲也:AIDS関連リンパ腫. 内科 80:520-522, 1997.

• 6) Ruiz A, Ganz WI, Post MJD et al.:Use of Thallium-201 Brain SPECT to Differentiate Cerebral Lymphoma from Toxoplasma Encephalitis in AIDS. Patients Am J Neuroradiol 15:1885-1894, 1994.

• 7) Pierce MA, Johnson MD, Maciunas RJ et al.:Evaluating Contrast-Enhancing Brain Lesions in Patients with AIDS by Using Positron Emission Tomography. Ann Intern Med 123:594-598, 1995.
  pubmed

• 8) Forsyth PA, Yahalom J, DeAngelis LM:Combinedmodality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology 44:1473-1479, 1994.
  pubmed

• 9) Aviles A, Nambo MJ, Halabe J:Treatment of acquired immunodeficiency syndrome-related lymphoma with a standard chemotherapy regimen. Ann Hematol 78:9-12, 1999.
  pubmed

P.168 掲載の参考文献

• 1) Aozasa K:Pyothorax-associated lymphoma. Int J Hematol 65:9-16, 1996.
  pubmed

• 2) Iuchi K, Aozasa K, Yamamoto S et al.:Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax:Summary of clinical and pathological findings in thirty-seven cases. Jpn J Clin Oncol 19:249-257, 1989.

• 3) 吹野俊介, 深田民人, 井上明彦・他:人工気胸術後慢性結核性膿胸壁より発生したT細胞型非ホジキン悪性リンパ腫の1手術例. 日本胸部外科学会誌 40:113-117, 1992.

• 4) Kuriyama Y, Funato K, Nakajima A et al.:The detection of Epstein-Barr virus in a pyothorax-associtaed lymphoma with T-cell phenotype(submitted).

• 5) Mori N, Yatabe Y, Narita M et al.:Pyothorax-associated lyrnphoma:An ususal case with biphenotypic character of T and B cells. Am J Surg Pathol 20:760-766, 1996.

• 6) Nakamura S, Sasajima Y, Koshikawa T et al.:Ki-1 (CD30) positive anaplastic large cell lymphoma of T-cell phenotype developing in association with long-standing tuberculous pyothorax:report of a cese with detection of Epstein-Barr virus genome in the tumor cells. Hum Pathol 26:1382-1385, 1995.

• 7) Fukuyama M, Ibuka T, Hayashi Y et al.:Epstein-Barr virus in pyothorax-associated lymphoma. Am J pathol 143:1044-1049, 1993.

• 8) Kawa K. :Epstein-Barr virus associated diseases in human. Int J Hematol 71:108-117, 2000.
  pubmed

• 9) Kinoshita T, Ishii K, Taira Y et al.:Malignant lymphoma arising chronic tuberculous empyema. Acta Radiologica 38:833-835, 1997.
  pubmed

• 10) 柏原光介, 中村博幸, 柳生久永・他:血清neuron specific enolase高値を呈した慢性膿胸後リンパ腫の1例. 日本呼吸器学会誌 37:846-850, 1999.

• 11) Aozasa K, Ohsawa M, Luchi K et al:Prognostic factor for pleural lymphoma patients. Jpn J Clin Oncol 121:417-421, 1991.

• 12) 吉冨 淳, 千田金吾, 須田隆文・他:胸壁開窓術後に化学療法を施行した膿胸関連リンパ腫の1例. 日本呼吸器学会誌 37:619-622, 1999.

• 13) Aruga T, Itami J, Nakajima K et al.:Treatment of pyothorax-associated lymphoma. Radiother Oncol 56:59-63, 2000.
  pubmed

P.172 掲載の参考文献

• 1) 白井達男, 金子晴生, 新津 望・他:老年者悪性リンパ腫の臨床的研究. 日老会誌 32:560-565, 1995.

• 2) 森眞由美:高齢者悪性リンパ腫の特徴と治療. 医学のあゆみ 152:968-972, 1990.
  Medical*Online

• 3) Fisher RI, Gaynor ER, Dahlberg S et al.:Comparison of standard regimen(CHOP) with three intensive chemotherapy regimens for advanced non Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993.
  pubmed

• 4) 森眞由美, 村井善郎, 鈴木憲史・他:高齢者非Hodgkinリンパ腫に対するCHOP療法. 臨床血液 40:199-204, 1999.

• 5) Tirelli U, Errante D, Van Glabbeke M et al.:CHOP is standard regimen in patient≧70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma:Results of a randomized study of the European Organization for research and treatment of cancer lymphoma cooperative study group. J Clin Oncol 16:27-34, 1998.

P.176 掲載の参考文献

• 1) 佐々木邦明, 大持 寛, 河合 進・他:小児悪性リンパ腫568例の病態と予後. 日本小児科学会雑誌 91:690-700, 1987.

• 2) 小泉晶一:非ホジキンリンパ腫. 小児がんの診断と治療. 診断と治療社, 1998, p236-241.

• 3) 小児腫瘍組織分類図譜(第2篇). 小児悪性リンパ腫および類縁疾患. 日本病理学会小児腫瘍組織分類委員会, 金原出版, 1990.

• 4) Murphy SB, Fairclough DL, Hutchison RE et al.:Non-Hodgkin's Lymphomas of Childhood:An Analysis of the Histology, Staging, and Response to Treatment of 338 Cases at a Single Institution. J Clin Oncol 7:186-193, 1989.

• 5) TCCSG・NHL委員会:TCCSG・NHLプロトコールT-8801, B-8801, B-9203の成績. 日本小児血液学会雑誌 9:296, 1995.

• 6) Lukes RJ:Report of the Momenclature Committee. Cancer Res 26:1311, 1966.

• 7) Schnitzer B, Nishiyama RH, Heidelberger KP et al.:Hodgkin's Disease in Children. Cancer 31:560-567, 1973.
  pubmed

• 8) Lister TA, Crowther D, Sutcliffe SB et al.:Report of a Committee Convenced To Discuss the Evaluation and Staging of Patients with Hodgkin's Disease:Cotswolds Meeting. J Clin Oncol 7:1630-1636, 1989.

6 リンパ腫各論・その他・含むマネージメント編

P.180 掲載の参考文献

• 1) 高田賢蔵:EBウイルスによる発癌機構. Molecular Medicine 34:1376-1382, 1997.

• 2) Xu ZG, lwatsuki K, Ohtsuka M et al.:Polymorphosm analysis of Epstein-Barr virus isolates from patients with cutaneous natural killer/T-cell lymphoproliferative disorders:a possible relation on the endemic occurrence of these diseases in Japan. J Med Virol 62:239-246, 2000.

• 3) 前川 出, 塩田真美, 森 茂郎:Epstein-Barr virus(EBV)の関与する血液系腫瘍. 血液フロンティア 9:1013-1016, 1999.

• 4) Lucas KG, Pollok K, Emanuel DJ:Post-Transplant EBV induced lymphoproliferative disorders. Leuk Lymphoma 25:1-8, 1997.
  pubmed

• 5) Ohyashiki JH, Abe K, Ohyashiki K et al.:Quantification of human herpesvirus 6 in healthy volunteers and patients with lymphoproliferative disorders by PCR-ELISA. Leuk Res 23:625-630, 1999.
  pubmed

• 6) Klepfish A, Sarid R, Shtalrid M et al.:Primary effusion lymphoma in HIV-negative patients-a distinct clinical entity. Leuk Lymphoma 41:439-443, 2001.
  pubmed

• 7) Daibata M, Hatakeyama N, Kamioka M et al.:Detection of human herPesvirus 6 and JC virus in progressive multifocal leukoencephalopathy complication follicular lymphoma. Am J Hematol 67:200-205, 2001.

• 8) ニコラス・レガシュ著, 二階堂行彦訳:襲いくるウイルスHHV-6. ニュートンプレス, 東京, 2000.

• 9) 葛島清隆:細胞性免疫からみたEpstein-Barr virus感染症. ウイルス 51:43-49, 2001.

P.183 掲載の参考文献

• 1) Lucas KG, Pollok K, Emanuel DJ:Post-Transplant EBV induced lymphoproliferative disorders. Leuk Lymphoma 25:1-8, 1997.
  pubmed

• 2) Knowles DM:Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol 12:200-217, 1999.
  pubmed

• 3) Orii T, Ohkohchi N, Kikuchi H et al.:Usefulness of quantitative real-time polymerase chain reaction in following patients with Epstein-Barr virus infection after liver transplantation. Clin Transplantation 14:308-317, 2000.
  pubmed

• 4) 大屋敷純子, 山本興太郎, 鈴木章孝・他:血液疾患におけるライトサイクラーを用いたDNA診断の実際. 臨床血液 42:468-471, 2001.

• 5) Kuzushima K, Kimura H, Hoshino Y et al.:Longitudinal dynamics of Epstein-Barr virus-specific cytotoxic T lymphocytes during posttransplant lymphoproliferative disorders. J Infect Dis 182:937-940, 2000.

• 6) Kapelushnik J, Ariad S, Benharroch D et al.:Post renal transplantation human herpesvoris 8-associated lymphoproliferative disorder and Kaposi's sarcoma. Br J Haematol 113:425-428, 2001.

• 7) Papadopoulos EB, Landanyi M, Emanuel D et al.:Infusions of donor leukocytes as treatment of Epstein-Barr virus associated lymphoproliferative disorders complicating allogeneic marrow transplantation. N Engl J Med 330:1185-1191, 1994.

• 8) Savoldo B, Heslop HE, Rooney CM:The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients. Leuk Lymphoma 39:455-464, 2000.
  pubmed

P.187 掲載の参考文献

• 1) Carbone PP, Kaplan HS, Musshoff K et al.:Report of the committee on Hodgkin's disease staging classification. Cancer Res 31:1860-1861, 1971.

• 2) Lister TA, Crowther D, Sutcliffe SB et al:Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease:Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989.
  pubmed

• 3) 栗山 謙, 外山圭助:悪性リンパ腫. Medical Practice 14(臨時増刊号 実地医家のための癌の臨床ガイド):373-384, 1997.

• 4) Hasenclever D, Diehl V, Armitage JO et al.:Aprognostic score for advanced Hodgkin's disease. N Engl J Med 339:1506-1514, 1998.

• 5) The International Non-Hodgkin's Lymphoma Prognostic Factors Project:A Predictive Model for Aggressive Non-Hodgkin's Lymphoma. N Engl J Med 329:987-994, 1993.

• 6) Hermans J, Krol AD, van Groningen K at al.:International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 86:1460-1463, 1995.

7 リンパ腫症例編

P.197 掲載の参考文献

• 1) Harris NL, Isaacson PG:What are the criteria for distinguishing MALT from non-MALT lymphoma at extranodal sites? Am J Clin Pathol 111:s126-s132, 1999.
  pubmed

• 2) Isaacson PG:Mucosa-associated lymphoid tissue lymphoma. Semin Hematol 36:139-147, 1999.
  pubmed

• 3) Jaffe ES:Relationship of classification to biologic behavior of non-Hodgkin's lymphomas. Semin Oncol 13(4 suppl. 5) :3-9, 1986.

• 4) Cavalli F:Extranodal lymphomas. The non-Hodgkin's lymphomas. Second edition(Magrath IT) , Arnold, London, 1997, p 1007-1030.

P.200 掲載の参考文献

• 1) Cohen PL, Brooks JJ:Lymphomas of the breast. Cancer 67:1359-1369, 1991.
  pubmed

• 2) Hakoda Y, Gotoh A, Kuriyama Y et al.:Breast MALT lymphoma:potential relationship between hormonal environment and female sex hormone receptor expression in lymphoma cells. Leuk Lymphoma 42:1157-1159, 2001.
  pubmed

• 3) Gopal S, Awasthi S, Elghetany MT:Bilateral breast MALT lymphoma:a case report and review of the literature. Ann Hematol 79:86-89, 2000.
  pubmed

P.204 掲載の参考文献

• 1) 栗山 謙, 外山圭助:悪性リンパ腫とリンパ性白血病の違いは. 臨床医 22:1831-1833, 1996.

• 2) Rohatiner A, Lister TA:Follicular lymphomas. The non-Hodgkin's lymphomas. Second edition(Magrath IT) , Arnold, London, 1997, p867-896.

• 3) Hainsworth JD:Monoclonal antibody therapy in lymphoid malignancies. Oncolologist 5:376-384, 2000.
  pubmed

P.208 掲載の参考文献

• 1) Grillo-Lopez AJ, White CA, Dallaire BK, Varns CL, Shen CD, Wei A, Leonard JE, McClure A, Weaver R, Cairelli S, Rosenberg J:Rituximab:the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 1(1):1-9, 2000.

• 2) Petryk M, Grossbard ML:Hematologic malignancies. Oncologist 6 (4) :317-326, 2001.
  pubmed

P.212 掲載の参考文献

• 1) The Non-Hodgkin's Lymphoma Classification Project:A clinical evaluation of the International Lymphoma Study Group Classification of the non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997.

• 2) Piro LD, White CA, Grillo-Lopez AJ et al.:Extended Rituximab(anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10:655-661, 1999.

• 3) Foran JM, Gupta RK, Cunningham D et al.:A UK multicentre phase II study of rituximab(chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 109:81-88, 2000.

P.215 掲載の参考文献

• 1) 吉野 正, 赤木忠厚:低悪性度B細胞性リンパ腫の主な疾患単位と鑑別診断. 血液・腫瘍科 42:325-332, 2001.

P.219 掲載の参考文献

• 1) Diebold J, Molina T, Tissier F:Waldenstrom's macroglobulinemia is a biological syndrome which may occur durng the evolution of different types of low grade B cell lymphoma. Leukemia 13:1637-1638, 1999.

• 2) Bain GO, Belch A:Nodular mixed cell lymphoma with monoclonal gammopathy. Am J Clin Pathol 76:832-837, 1981.
  pubmed

P.222 掲載の参考文献

• 1) Kumar S, Green GA, Teruya-Feldstein J et al.:Use of CD23 (BU38) on paraffin sections in the diagnosis of small lymphocytic lymphoma and mantle cell lymphoma. Mod Pathol 9, 1996.

• 2) 須知泰山, 菊池昌弘:悪性リンパ腫アトラス. 分光堂, 東京, 2000.

P.225 掲載の参考文献

• 1) Alizadeh AA, Eisen MB, Davis RE et al.:Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000.
  pubmed

P.229 掲載の参考文献

• 1) The International Non-Hodgkin's Lymphoma Prognostic Factors Project:A predictive model for aggressive non-Hodgkin's Lymphoma. N Engl J Med 329:987-994, 1993.

• 2) Alizadeh AA, Eisen MB, Davis RE et al.:Distinct types of diffuse large B-cell lmphoma identified by gene expression profiling. Nature 403:503-511, 2000.

P.233 掲載の参考文献

• 1) Silvestri F, Ermacora A, Sperotto A, Patriarca F, Zaja F, Damiani D, Fanin R, Baccarani M:Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol 108(2) :394-396, 2000.
  pubmed

P.237 掲載の参考文献

• 1) 北村 聖:高齢者悪性リンパ腫の治療方針. 日内会誌 90:1010-1018, 2001.

• 2) Ballester OF, Moscinski L, Spiers A et al.:Non-Hodgkin's lymphoma in the older person;A review. J Am Geriatr Soc 41:1245-1254, 1993.

P.240 掲載の参考文献

• 1) 松野吉宏:節外性大細胞型Bリンパ腫の特性と主な疾患単位. 血液・腫瘍科 42:333-339, 2001.

• 2) Heinzerling LM, Urbanek M, Funk JO, Peker S, Bleck O, Neuber K, Burg G, von Den Driesch P, Dummer R:Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody(rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 89:1835-1844, 2000.
  pubmed

P.244 掲載の参考文献

• 1) 松岡雅雄:HTLV-IプロウイルスからみたATL発症機構. 血液・腫瘍科 38:200-206, 1999.

• 2) Ohshima K, Suzumiya J, Kato A et al.:Clonal HTLV-I-infected CD4+ Tlymphocytes and non-clonal non-HTLV-I-infected giant cells in incipient ATLL with Hodgkin-like histologic features. Int J Cancer 72:592-598, 1997.

P.248 掲載の参考文献

• 1) Spits H, Lanier LL, Phillips JH:Development of human T and natural killer cells. Blood 85:2654-2670, 1995.

• 2) 押味和夫:NK細胞-基礎から臨床へ. 金原出版, 1993.

• 3) Nakamura S, Katoh E, Koshikawa T et al.:Clinicopathologic study of nasal T/NK-cell lymphoma among Japanese. Pathol Int 47:38-53, 1997.
  pubmed

• 4) Nademanee A, Molina A, O'Donnell MR et al.:Results of high-dose therapy and autologous bone marrow/stem cell trasplantation during remmision in poor-risk inter-mediate-and high-grade lymphoma:international index and high-intermediate risk group. Blood 90:3844, 1997.

P.252 掲載の参考文献

• 1) Jaffe ES:Classification of Natural Killer Cell and NK-like T-Cell Lymphoma. Blood 87:1207-1210, 1996.
  pubmed

• 2) Macon WR et al.:Natural Killer-Like T-Cell Lymphomas:Agressive lymphomas of T-Large Granular Lymphocyte. Blood 87:1474-1483, 1996.

• 3) Sumi M et al.:Natural Killer cell lymphoma in gastrointestinal system. Leuk Lymphoma, (in press) .

P.255 掲載の参考文献

• 1) 押味和夫:NK細胞腫瘍. 臨床血液 41:169-172, 2000.

• 2) Spits H et al.:Development of human T and natural killer cells. Blood 85:2654-2670, 1995.

• 3) Ko YH et al.:Blastic NK-cell lymphoma expressing terminal deoxynucleotidyl transferase with Homer-Wrigt type pseudorosettes formation. Histopathology 33:547-553, 1998.

• 4) Suzuki R, Nakamura S:Malignancies of natural killer (NK) cell precursor:myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/ leukemia. Leuk Res 23:615-624, 1999.
  pubmed

• 5) Bagot M et al.:Do primary cutaneous non-T non-B CD4+ CD56+ lymphomas belong to the myelo-monocytic lineage? J Invest Dermatol 111:1242-1243, 1998.

• 6) Serke S et al.:Circulating CD4+ T lymphocytes with intracellular but no surface CD3 antigen in five of seven patients consecutively diagnosed with angioimmunoblastic T-cell lymphoma. Cytometry 42:180-187, 2000.
  pubmed

• 7) Picker LJ et al.:Discordant expression of CD3 and T-cell receptor beta-chain antigens in T-lineage lymphomas. Am J Pathol 129:434-444, 1987.

• 8) Emile JF et al.:CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood 87:1466-1473, 1996.
  pubmed

• 9) 本多聖子, 伊藤良和, 小田和昌彦・他:T細胞起源と考えられたCD56陽性CD4陽性非Hodgkinリンパ腫. 臨床血液 42:420-425, 2001.

P.259 掲載の参考文献

• 1) Aozasa K:Pyothorax-associated lymphoma. Int J Hematol 65:9-16, 1996.
  pubmed

• 2) Kawa K:Epstein-Barr virus-associated diseases in human. Int J Hematol 71:108-117, 2000.
  pubmed

• 3) Kuriyama Y, Nakajima A, Shimizu N et al.:Detection of Epstein-Barr Virus in a Pyothorax-associated Lymphoma with T-Cell Phenotype. Haematologica 87:ECR28, 2002.

• 4) 柏原光介, 中村博幸, 柳生久永・他:血清neuron specific enolase高値を呈した慢性膿胸後リンパ腫の1例. 日本呼吸器学会誌 37:846-850, 1999.

P.263 掲載の参考文献

• 1) 本告 匡, 須知泰山:T-zone lymphoma, lymphoepithelioid lymphoma(Lennert's lymphoma) and angioimmunoblastic lymphoma(IBL-like T-cell lymphoma) . 病理と臨床 12(臨時増刊号 リンパ節病変) :112-116, 1994.

• 2) Patsouris E, Engelhard M et al.:Lymphoepithelioid cell lymphoma(Lennert's lymphoma) :clinical features derived from analysis of 108 cases. Br J Haematol 84:346-348, 1993.

P.266 掲載の参考文献

• 1) Harris NL, Jaffe ES, Diebold J et al.:World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues:report of the Clinical Advisory Committee meeting-Airlie House, Virginia. J Clin Oncol 17:3835-3849, 1999.
  pubmed

• 2) 阿部達生・他:造血器腫瘍アトラス. 日本医事新報社, 2000, p126-134.

• 3) Horning SJ, Rosenberg SA, Hoppe RT:Brief chemotherapy (Stanford V) and adjubant radiotherapy for bulky or advanced Hodgkin's disease:an update. Ann Oncol 7:105, 1996.
  pubmed

• 4) Diehl V, Franklin J, Hasenclever D et al.:Beacopp, anew dose-escalted and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma:interim report from a trial of the German Hodgkin's lymphoma Study Group. J Clin Oncol 16:3810-3815, 1998.